EPHA3 was also expressed on a subset of immunophenotypically defined LSC, CD34+ CD38– CD123+, in AML patients, and the high-affinity recombinant antibody to EPHA3, KB004, reduced the numbers of long-term culture initiating cells ex vivo (Palath et al., 2010). This evidence concerns the gene CD34 and acute myeloid leukemia.